| Ytd | -78.74% | |
| 1y | -50.26% |
| Open | 1.93 | Prev Close | 1.93 | Low | 1.91 | High | 1.94 | Mkt Cap | 98.81M |
| Vol | 55.90K | Avg Vol | 1.91M | EPS | -2.17 | P/E | -0.89 | Forward P/E | -3.53 |
| Beta | -0.28 | Short Ratio | 11.39 | Inst. Own | 83.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-14 | 50-d Avg | 1.74 | 200-d Avg | 6.64 | 1yr Est | 27.00 |
ENGN News
enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company
Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litiga
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigat
enGene Therapeutics is rated Buy, trading below its $4.66/share cash floor despite weak Phase 2 data
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
LOS ANGELES--(BUSINESS WIRE)---- $ENGN--ENGN Investors Have Opportunity to Join enGene Therapeutics
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in H
enGene NASDAQ: ENGN reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEN
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims o
US stocks higher Thursday morning, Dow down 0.28%, Nasdaq up 0.50%, S&P 500 up 0.07%. Tech secto
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the “Compa
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasda
enGene Holdings Inc. (NASDAQ: ENGN - Get Free Report) has earned a consensus recommendation of "Mode
Executives from enGene (NASDAQ: ENGN) provided an update on the company's detalimogene program in no
